ReviewFrontiers in molecular biosciences2020
Nanotechnology-Based Strategies for Berberine Delivery System in Cancer Treatment: Pulling Strings to Keep Berberine in Power.
Review in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 93 citations in OpenAlex.
- Berberine inhibits gastric cancer progression by targeting canonical Wnt/β-catenin signaling in AGS cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A berberine-functionalized green silver nanoplatform for combined chemo-photodynamic therapy against breast cancer cells.Nanoscale advances · 2026Article
- Green-Synthesized Nanomaterials for Kidney Cancer: Current Progress and Future Perspectives.International journal of molecular sciences · 2026Review
- Targeting the Microbiota-Gut-Brain Axis: Emerging Nanomedicine Approaches for Neurodegenerative Diseases.The European journal of neuroscience · 2026Review
- Berberine as a Multifunctional Adjuvant in Cancer Therapy: Mechanistic Insights, Nanotechnological Strategies, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Berberine-entrapped albumin nanoparticles ameliorate chemically induced liver injury by restoring oxidative balance and autophagic-apoptotic crosstalk.Scientific reports · 2026Article
- Nanotechnology Meets Phytotherapy: A Comprehensive Review of Berberine in Cancer.Mini reviews in medicinal chemistry · 2026Review
- Mechanisms of Traditional Chinese Medicine-Derived Alkaloids in Colorectal Cancer Therapy: Molecular Targets, Preclinical Evidence, and Translational Prospects.Drug design, development and therapy · 2026Review
- Berberine as a Bioactive Alkaloid: Multi-Omics Perspectives on Its Role in Obesity Management.Metabolites · 2025Review
- Metal-based nanoplatforms for enhancing the biomedical applications of berberine: current progress and future directions.Nanomedicine (London, England) · 2025Review
- Comprehensive pharmacokinetic profiling and molecular docking analysis of natural bioactive compounds targeting oncogenic biomarkers in breast cancer.Scientific reports · 2025Article
- Natural drug delivery systems for the treatment of neurodegenerative diseases.Molecular biology reports · 2025Review
- Berberine pharmacological properties and therapeutic potential across cancer, digestive, metabolic, cardiovascular, and neurological diseases: an update review.EXCLI journal · 2025Review
- Oral Administration of Berberine Hydrochloride Based on Chitosan/Carboxymethyl-β-Cyclodextrin Hydrogel.Polymers · 2024Article
- Nanocarriers for natural polyphenol senotherapeutics.Aging cell · 2024Review
- Berberine Improves Cancer-Derived Myocardial Impairment in Experimental Cachexia Models by Targeting High-Mobility Group Box-1.International journal of molecular sciences · 2024Article
- Comparison of the protective effects of CS/TPP and CS/HPMCP nanoparticles containing berberine in ethanol-induced hepatotoxicity in rat.BMC complementary medicine and therapies · 2024Article
- Investigation of Antioxidant and Anti-inflammatory Properties of Berberine Nanomicelles:Current drug delivery · 2024Article
- Block Copolymer Encapsulation of Disarib, an Inhibitor of BCL2 for Improved Chemotherapeutic Potential.ACS omega · 2023Article
- Development of Gelled-Oil Nanoparticles for the Encapsulation and Release of Berberine.ACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a multifactorial disease characterized by complex molecular landscape and altered cell pathways that results in an abnormal cell growth. Natural compounds are target-specific and pose a limited cytotoxicity; therefore, can aid in the development of new therapeutic interventions for the treatment of this versatile disease. Berberine is a member of the protoberberine alkaloids family, mainly present in the root, stem, and bark of various trees, and has a reputed anticancer activity. Nonetheless, the limited bioavailability and low absorption rate are the two major hindrances following berberine administration as only 0.5% of ingested berberine absorbed in small intestine while this percentage is further decreased to 0.35%, when enter in systemic circulation. Nano-based formulation is believed to be an ideal candidate to increase absorption percentage as at nano scale level, compounds can absorb rapidly in gut. Nanotechnology-based therapeutic approaches have been implemented to overcome such problems, ultimately promoting a higher efficacy in the treatment of a plethora of diseases. This review present and critically discusses the anti-proliferative role of berberine and the nanotechnology-based therapeutic strategies used for the nano-scale delivery of berberine. Finally, the current approaches and promising perspectives of latest delivery of this alkaloid are also critically analyzed and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.